Browsing tag:

multiple sclerosis


Known as the brand name anti-epileptic drug Dilantin, Phenytoin has recently piqued the interests of Multiple Sclerosis research and development teams. Study results shared from the National Hospital for Neurology and Neurosurgery in London have been hopeful for patients with MS who were treated with Phenytoin, in response to their cases of acute optic neuritis.[…]

Read More

Known as the brand name Campath, which is marketed by Genzyme, Alemtuzumab is a proven therapy for leukemias, lymphomas and recently, multiple sclerosis. As a monoclonal antibody Alemtuzumab effectively binds to the CD52 protein which occurs on cancerous B and T cell lymphocytes. After attaching to the protein on the cells Alemtuzumab elicits other immune[…]

Read More

Exciting news was revealed from Genzyme at the beginning of February 2014, with the announcement that their formidable multiple sclerosis drug, Alemtuzumab, had been approved for use in Mexico. Known as the brand name Lemtrada, Alemtuzumab is specifically effectual for patients with relapsing remitting multiple sclerosis, also coined RRMS. This extremely common and debilitating form[…]

Read More

On November 22, 2013 Health Canada approved the novel once daily pill Teriflunomide for the treatment of Multiple Sclerosis. Approved by the FDA in September of 2012, this efficacious drug is targeted for treating patients with relapsing remitting multiple sclerosis, or RRMS. The ease of use for this 14 milligram pill, taken only once a[…]

Read More

Glatiramer, CAS# 28704-27-0, and Glatiramer Acetate, CAS# 147245-92-9, are also known as Copaxone. In the spotlight recently, Copaxone’s patent is due to expire on May 24, 2014. The flurry of interest regarding Copaxone follows the devastating diagnosis of Multiple Sclerosis for beloved reality star Jack Osbourne. In mid June of 2012 reports surfaced about Jack’s[…]

Read More

Dextromethorphan Hydrobromide is a well known cough suppressant drug. During a research study jointly funded by the CIA and the US Navy, Dextromethorphan Hbr was established as a non-addictive substitute for Codeine, a common cough depressant. Codeine is an analgesic, which is addictive in nature. In 1958, the U.S. Food and Drug Administration approved this[…]

Read More